0
Letters |

Developers of the Hepatitis B Vaccine—Reply

R. Palmer Beasley, MD
JAMA. 2009;302(23):2552. doi:10.1001/jama.2009.1833.
Text Size: A A A
Published online

Extract

In Reply: Dr Braillon provides a reminder of the pioneering efforts of Philippe Maupas of the University of Tours before his sudden death in 1981. I was fortunate to have had Maupas and his colleagues as good friends in the stimulating world of early hepatitis B virus (HBV) research.

Maupas was among the many contributors to the successful development of the HBV vaccine. My commentary focused on the contributions of Maurice Hilleman and his colleagues since it was a celebration of their first publication on this successful pioneering vaccine that became the basis for the eventual World Health Organization HBV control program as the first human cancer vaccine. Other important early contributors included Saul Krugman, who was the first person to make an HBV vaccine when he showed that heat-inactivated HBV-containing sera induced a durable protective immune response; and Robert Purcell at the National Institutes of Health, who also developed an independent early HBV vaccine. The important efforts of Maupas were carried on for many years after his death by his Tours colleagues Pierre Coursaget and Alain Goudeau and became the basis of the HBV vaccine development of the Institut Pasteur in Paris.

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

December 16, 2009
Alain Braillon, MD
JAMA. 2009;302(23):2552. doi:10.1001/jama.2009.1832.
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs